Company news

Allogene Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

November 6, 2024

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunothe...

November 4, 2024

Allogene Therapeutics Announces Participation in November Investor Conferences

November 3, 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

October 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

October 28, 2024

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

September 29, 2024

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

September 25, 2024

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

August 6, 2024

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

July 30, 2024

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

June 30, 2024

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

June 19, 2024

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 22, 2024

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 12, 2024

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 12, 2024

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 5, 2024

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

April 25, 2024

Allogene Therapeutics Announces Q2 Investor Conference Participation

April 8, 2024

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

March 13, 2024

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

March 11, 2024

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

March 4, 2024

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

February 27, 2024

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

February 15, 2024

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 3, 2024

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 3, 2024

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

December 8, 2023

Allogene Therapeutics Announces Participation in December Investor Conference

November 30, 2023

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

November 2, 2023

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

November 2, 2023

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

November 1, 2023

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

November 1, 2023

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

October 25, 2023

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

October 15, 2023

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 26, 2023

Allogene Therapeutics Announces Participation in September Investor Conference

September 4, 2023

Allogene Therapeutics Appoints Earl Douglas as General Counsel

August 13, 2023

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 1, 2023

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

June 14, 2023

Allogene Therapeutics Announces Departure of Chief Financial Officer

June 13, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

June 8, 2023

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2023

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

May 23, 2023

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

May 10, 2023

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 2, 2023

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2023

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

April 24, 2023

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

April 19, 2023

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

April 16, 2023

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

April 12, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.